The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe. Some experts speculate that pharma firms may opt to delay or even forego launches in certain regions, while others downplay the potential MFN impact on the industry. Pharmas are left to navigate a complex set of intertwined global policy and strategic shifts.
In this report, discover how experts see U.S. MFN policy playing out, including the expected impact on pharma firms and the broader healthcare system, and what firms are doing to mitigate MFN risks.
